# Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide

> **NCT03191903** · PHASE3 · COMPLETED · sponsor: **Anika Therapeutics, Inc.** · enrollment: 576 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **COMBINATION_PRODUCT:** Cingal
- **DEVICE:** Monovisc
- **DRUG:** Triamcinolone Hexacetonide

## Key facts

- **NCT ID:** NCT03191903
- **Lead sponsor:** Anika Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2018-04-23
- **Final completion:** 2018-04-23
- **Target enrollment:** 576 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191903, "Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03191903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*